Recent Updates
Recently added Catalysts
EOLS Positive Sentiment

Evolus to Participate in Upcoming Investor Conferences in New York and London

Wednesday, October 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Evolus, Inc. will participate in two investor conferences in New York and London. The Stifel Healthcare Conference is scheduled for November 11, 2026, where management will engage in a fireside chat and hold investor meetings. This involvement reflects the company's commitment to investor relations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Evolus is actively engaging with investors.
  • Participation in major conferences indicates strong market presence.
  • Management's involvement in discussions may boost investor confidence.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~35 mo
Minimal dilution risk
Lead asset
Botulinum toxin, Type A
Phase 3 · Glabellar Frown Lines

Full Press Release Details

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will participate in two upcoming investor conferences in New York and London: The Stifel Healthcare Conference, where management will participate in a fireside chat and host investor meetings on Wednesday, November 11, 2026, in New York City. The fireside chat is scheduled for 2:0

Frequently Asked Questions

When will Evolus participate in investor conferences?

Evolus will participate on November 11, 2026.

What is the Stifel Healthcare Conference?

It is an investor conference where Evolus will engage with investors.

Where are the upcoming conferences taking place?

The conferences will be held in New York and London.

What will Evolus management do at the conferences?

They will participate in a fireside chat and host investor meetings.

ShareAdd on Google
Tags: EOLS Evolus investor conferences Stifel Healthcare Conference New York
Last updated: Oct 28, 2026

Biotech snapshot

Cash runway
$45M liquidity · $1M/mo burn
~35 mo
Minimal dilution risk
Lead asset
Botulinum toxin, Type APhase 3
Glabellar Frown Lines →